Literature DB >> 26126579

Serotonergic antidepressant use and the risk of fracture: a population-based nested case-control study.

C-Y Wang1, S-H Fu2, C-L Wang2, P-J Chen3, F-L L Wu4,5,6, F-Y Hsiao7,8,9.   

Abstract

UNLABELLED: This is the first study to investigate the association between the use of selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) and the risk of fractures using a nationwide representative cohort of ethnic Chinese. Current use of SSRI/SNRI and the co-morbidity, especially osteoporosis and history of falling, play an important role in the increased risk of fractures.
INTRODUCTION: This nested case-control study examines the association between the timing, intensity, and individual components of serotonergic antidepressant (including SSRIs and SNRIs) use and the risk of all-cause fracture.
METHODS: Using the 2002-2011 Taiwan National Health Insurance Research Database, we identified patients who received at least three prescriptions of antidepressants between January 1st 2002 and December 31st 2010 as our study cohort. In the study cohort, we identify 8250 patients who had first admission for fracture and 33,000 matched controls (1:4, matched by age, sex, and cohort entry date). Multivariate conditional logistic regression was used to estimate the association between the use of serotonergic antidepressants and the risk of fracture.
RESULTS: Current users of serotonergic antidepressants were associated with an increased risk of fracture (adjusted odds ratio (aOR) 1.16 [95 % confidence interval 1.07-1.25]). Furthermore, a higher risk of fractures was found in patients with osteoporosis (aOR 3.05 [2.73-3.42]) or a history of falling (aOR 6.13 [3.41-11.0]). The risks of fracture between SSRI and SNRI users were comparable.
CONCLUSION: Current use of SSRI/SNRI is associated with an increased risk of all caused fractures. Additionally, the co-morbidity, especially osteoporosis and a history of falling, plays an important role in the risk of fractures.

Entities:  

Keywords:  Falling; Fracture; Osteoporosis; Serotonergic antidepressants

Mesh:

Substances:

Year:  2015        PMID: 26126579     DOI: 10.1007/s00198-015-3213-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  31 in total

1.  Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture.

Authors:  Richard Hubbard; Paddy Farrington; Chris Smith; Liam Smeeth; Anne Tattersfield
Journal:  Am J Epidemiol       Date:  2003-07-01       Impact factor: 4.897

2.  Long-term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats.

Authors:  Björn I Gustafsson; Irene Westbroek; Jan H Waarsing; Helge Waldum; Erik Solligård; Anders Brunsvik; Sigbjørn Dimmen; Johannes P T M van Leeuwen; Harrie Weinans; Unni Syversen
Journal:  J Cell Biochem       Date:  2006-04-15       Impact factor: 4.429

3.  Adherence to treatment with selective serotonin reuptake inhibitors and the risk for fractures and bone loss: a population-based cohort study.

Authors:  Inbar Zucker; Gabriel Chodick; Leon Grunhaus; Ra'anan Raz; Varda Shalev
Journal:  CNS Drugs       Date:  2012-06-01       Impact factor: 5.749

4.  A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database.

Authors:  M L Murray; C S de Vries; I C K Wong
Journal:  Arch Dis Child       Date:  2004-12       Impact factor: 3.791

5.  Risk of nonvertebral fractures among elderly postmenopausal women using antidepressants.

Authors:  Véronique Rabenda; Olivier Bruyère; Jean-Yves Reginster
Journal:  Bone       Date:  2012-08-04       Impact factor: 4.398

Review 6.  Drug treatment as a cause of falls in old age. A review of the offending agents.

Authors:  A J Campbell
Journal:  Drugs Aging       Date:  1991 Jul-Aug       Impact factor: 3.923

Review 7.  Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studies.

Authors:  S J Warden; E M Haney
Journal:  J Musculoskelet Neuronal Interact       Date:  2008 Apr-Jun       Impact factor: 2.041

Review 8.  Risk of fractures with selective serotonin-reuptake inhibitors or tricyclic antidepressants.

Authors:  Regina Ginzburg; Enma Rosero
Journal:  Ann Pharmacother       Date:  2008-12-30       Impact factor: 3.154

9.  Trends in Prescribing of Selective Serotonin Reuptake Inhibitors and Other Newer Antidepressant Agents in Adult Primary Care.

Authors:  Paul A. Pirraglia; Randall S. Stafford; Daniel E. Singer
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-08

10.  The global burden attributable to low bone mineral density.

Authors:  L Sànchez-Riera; E Carnahan; T Vos; L Veerman; R Norman; S S Lim; D Hoy; E Smith; N Wilson; J M Nolla; J S Chen; M Macara; N Kamalaraj; Y Li; C Kok; C Santos-Hernández; L March
Journal:  Ann Rheum Dis       Date:  2014-04-01       Impact factor: 19.103

View more
  8 in total

1.  Are selective serotonin reuptake inhibitors associated with fractures?

Authors:  Sarah Drost; Anne Massicotte
Journal:  Can Pharm J (Ott)       Date:  2016-10-06

2.  Effects of drugs on bone metabolism in a cohort of individuals with traumatic spinal cord injury.

Authors:  Christina Kokorelis; Marlis Gonzalez-Fernandez; Marjorie Morgan; Cristina Sadowsky
Journal:  Spinal Cord Ser Cases       Date:  2019-01-16

3.  VITamin D and OmegA-3 TriaL (VITAL) bone health ancillary study: clinical factors associated with trabecular bone score in women and men.

Authors:  A L Goldman; C M Donlon; N R Cook; J E Manson; J E Buring; T Copeland; C Y Yu; M S LeBoff
Journal:  Osteoporos Int       Date:  2018-07-18       Impact factor: 4.507

4.  Emotional Blunting, Cognitive Impairment, Bone Fractures, and Bleeding as Possible Side Effects of Long-Term Use of SSRIs.

Authors:  Donatella Marazziti; Federico Mucci; Beniamino Tripodi; Manuel Glauco Carbone; Alessia Muscarella; Valentina Falaschi; Stefano Baroni
Journal:  Clin Neuropsychiatry       Date:  2019-04

5.  Current anti-depressant use is associated with cortical bone deficits and reduced physical function in elderly women.

Authors:  Sanchita Agarwal; Carmen Germosen; Nayoung Kil; Mariana Bucovsky; Ivelisse Colon; John Williams; Elizabeth Shane; Marcella D Walker
Journal:  Bone       Date:  2020-07-27       Impact factor: 4.398

6.  Risk of Fractures in Older Adults with Chronic Non-cancer Pain Receiving Concurrent Benzodiazepines and Opioids: A Nested Case-Control Study.

Authors:  Ye-Jin Kang; Min-Taek Lee; Myo-Song Kim; Seung-Hun You; Jae-Eun Lee; Joo-Hyeon Eom; Sun-Young Jung
Journal:  Drugs Aging       Date:  2021-06-23       Impact factor: 3.923

7.  Effects of depression and antidepressant medications on hip fracture: A population-based cohort study in Taiwan.

Authors:  Bi-Hua Cheng; Pau-Chung Chen; Yao-Hsu Yang; Chuan-Pin Lee; Ko-En Huang; Vincent C Chen
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

8.  Multinational comparison of new antidepressant use in older adults: a cohort study.

Authors:  Robyn Tamblyn; David Westfall Bates; David L Buckeridge; Will Dixon; Alan J Forster; Nadyne Girard; Jennifer Haas; Bettina Habib; Siyana Kurteva; Jack Li; Therese Sheppard
Journal:  BMJ Open       Date:  2019-05-14       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.